Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q2 2015 Earnings Presentation
15 slides from Torrent Pharmaceuticals's earnings presentation, Oct 30, 2015
Slide 1: The Next Level – Investor Update
The Next Level Investor Update 30th October, 2015 1
Slide 2: Torrent Pharma: Priority areas
\" Torrent Pharma: Priority areas —————————————— India — The Next Level USA — The Next level Brazil, Philippines & Europe — Outlook & priorities R&D — Pipeline & NDDS
Slide 3: Torrent Pharma – Priorities India & USA
Torrent Pharma – Cutting Edge Research Modern Manufacturing Facilities Among the leading Indian companies: Leveraging strengths Strengthened USA portfolio inspite of late entry – Poised to scale up Priorities – India & USA 3
Slide 4: India Business
India Business Changing gears 4
Slide 5: Torrent Pharma – India Business
Torrent Pharma – India Business History 4 decades of presence Started the concept of Niche marketing Driven by CNS, CND therapies in the early years Present Ranked among the top 15 companies Post Elder-acquisition – strengths in Women Healthcare, Nutraceuticals, Pain/Wound management Relentless focu
Slide 6: The Next levels – Growth drivers
The Next levels – Growth drivers New Therapies • Cosmetic dermatology • Rheumatology • Nephrology • Respiratory Science Specialty • Hepatology Best-in-Class margins • Through • Hygiene • MR Productivity Productivity • Rx-driven specialty business model Back to the glory of TURANT • 1st time launches
Slide 7: India & Other BG Markets – Driven by Science
India & Other BG Markets – Driven by Science Driven by Science • Marketing model driven by Science, Knowledge upgradation & support for upcoming medical practitioners SGPP • Shared Global Principles for Professionals • Guiding force for marketing for all BG markets • Defines global minimum standards
Slide 8: USA
USA New strengths & capabilities 8
Slide 9: Torrent Pharma – USA
Torrent Pharma – USA History Late Entry into the USA market Generic presence Present Among the top 10 Indian cos. In USA Wide product portfolio across therapies Highest per product revenue – Robust product selection Anchor customers – Enabling strong presence Future Ramping up ANDA filing rate Inorg
Slide 10: The Next levels - USA
The Next levels - USA Wider presence • Product portfolio expansion across therapies Dahej Facility • Vertical integration • Agility & Speed for US market Complex generics • Dermatology • Oncology R&D & ANDA speed • Augmented R&D Spends • ANDA filings accelerated from Q1 2016-17 10
Slide 11: Research & Development
Torrent R&D Center (Artistic image) Research & Development An eye on the future 11
Slide 12: Realizing R&D Pipeline & NDDS Synergies
Realizing R&D Pipeline & NDDS Synergies across Common pipeline Maximum synergies out of a Novel Drug Delivery systems common Branded generics pipeline – India business + Other Proprietary platforms: Foams, Ramping up R&D Spend geographies Long Acting injections (Unmet patient needs) Enhanced ANDA Fi
Slide 13: Torrent Pharma: The Next levels
Torrent Pharma: The Next levels 13
Slide 14: Europe & Brazil
Europe & Brazil Europe • Priority Areas – UK, Germany • Stronger participation in the German tender business; unable to participate today for larger tenders owing to supply constraints • Outlook – Supply issues resolved with commissioning of Dahej Facility Brazil & Philippines • Entry into new thera
Slide 15: Thank You
Thank You Disclaimer: No part of this presentation may be reproduced, quoted or circulated without prior written approval from Torrent Pharma Ltd. This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations.
Torrent Pharmaceuticals — Q2 2015 Earnings Presentation on 6ix